Brief: Mabion Signs Annex To Financing Deal With MFiPR
April 19 (Reuters) - Mabion SA MABP.WA :
* SIGNS ANNEX TO FINANCING DEAL
* UNDER ANNEX, EXPENSE ELIGIBILITY PERIOD FOR PROJECT HAS
BEEN
EXTENDED UNTIL DEC 31, 2023
* ALSO UNDER ANNEX, AS COMPANY INTRODUCED NEW RESEARCH AREA
(VACCINE THERAPY) TO PROJECT, ITS AIM AS WELL AS MATERIAL AND
FINANCIAL SCOPE OF PROJECT HAS CHANGED
* FINANCING DEAL WAS SIGNED WITH MFIPR ON NEW-GEN MEDICINE
PROJECT
Source text for Eikon: ID:nEM6YjJjga
Further company coverage: MABP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects